Sequent Scientific Ltd Stock Price Today (NSE: SEQUENT)
Fundamental Score
Sequent Scientific Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sequent Scientific Ltd share price today is ₹188.78, up +0.00% on NSE/BSE as of 16 September 2026. Sequent Scientific Ltd (SEQUENT) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.24K (Cr). The 52-week high for SEQUENT share price is ₹257.85 and the 52-week low is ₹117.35. At a P/E ratio of 61.29x, SEQUENT is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.05% and a debt-to-equity ratio of 0.17.
Sequent Scientific Ltd Share Price Chart — NSE/BSE Historical Performance
Sequent Scientific Ltd share price chart: -13.96% return over the past month. 52-week high ₹257.85, 52-week low ₹117.35.
Sequent Scientific Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹185.40 | ₹192.50 | ₹185.00 | ₹188.78 | 9.65L (Cr) | |
| ₹186.54 | ₹187.12 | ₹178.13 | ₹179.89 | 10.40L (Cr) | |
| ₹190.01 | ₹194.76 | ₹188.00 | ₹188.43 | 5.46L (Cr) | |
| ₹192.00 | ₹194.69 | ₹189.00 | ₹189.71 | 5.92L (Cr) | |
| ₹191.15 | ₹199.40 | ₹191.15 | ₹195.32 | 7.97L (Cr) | |
| ₹195.10 | ₹195.78 | ₹190.50 | ₹192.50 | 7.45L (Cr) | |
| ₹196.65 | ₹198.73 | ₹190.90 | ₹194.67 | 8.26L (Cr) | |
| ₹196.06 | ₹199.30 | ₹190.71 | ₹197.30 | 9.69L (Cr) | |
| ₹194.74 | ₹199.10 | ₹191.45 | ₹196.06 | 6.95L (Cr) | |
| ₹199.00 | ₹200.82 | ₹195.00 | ₹195.32 | 5.00L (Cr) |
Sequent Scientific Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹202.20 | ₹208.98 | ₹178.13 | ₹188.78 | -6.64% | |
| ₹204.00 | ₹240.00 | ₹197.10 | ₹213.08 | +4.45% | |
| ₹208.44 | ₹211.39 | ₹188.00 | ₹203.61 | -2.32% | |
| ₹224.60 | ₹228.00 | ₹193.00 | ₹208.54 | -7.15% | |
| ₹215.99 | ₹257.85 | ₹210.57 | ₹223.46 | +3.46% | |
| ₹186.29 | ₹220.45 | ₹186.06 | ₹214.61 | +15.20% | |
| ₹182.19 | ₹209.00 | ₹181.90 | ₹186.29 | +2.25% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sequent Scientific Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sequent Scientific Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SEQUENT across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Excellent ROCE Performance (19.05%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (455.37%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (129.02%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (20.23% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (15.00% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.68x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.73)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹239.64 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (61.31%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 61.29x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (6.70x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (2.72% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sequent Scientific Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sequent Scientific Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sequent Scientific LtdSequent Scienti...Selected✓ SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1851.80₹1852 | ₹444302.37₹444302.37 | 36.74Average 36.7 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9421.00₹9421 | ₹249656.50₹249656.50 | 85.48Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4948.00₹4948 | ₹167470.01₹167470.01 | 79.04Average 79.0 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1124.20₹1124 | ₹112195.16₹112195.16 | 25.05Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1372.20₹1372 | ₹110853.17₹110853.17 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.00₹1941 | ₹104862.52₹104862.52 | 95.80Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1670.20₹1670 | ₹96103.31₹96103.31 | 26.10Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1136.80₹1137 | ₹94922.80₹94922.80 | 29.38Average 29.4 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2071.50₹2072 | ₹94719.34₹94719.34 | 17.12Average 17.1 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2259.00₹2259 | ₹93296.70₹93296.70 | 45.65Average 45.6 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price444302.37 Cr
- Divi's Laboratories Limited share price249656.50 Cr
- Torrent Pharmaceuticals Limited share price167470.01 Cr
- Zydus Lifesciences Limited share price112195.16 Cr
- Cipla Limited share price110853.17 Cr
Sequent Scientific Ltd PE Ratio History
Historical price-to-earnings ratio for SEQUENT — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.85 | ₹208.54 | 245.3x |
| FY 2022 | ₹1.63 | ₹87.60 | 53.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sequent Scientific Ltd Dividend History
Annual cash dividends paid by SEQUENT — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹12.34 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sequent Scientific Ltd Quarterly Performance
Latest quarterly metrics for SEQUENT — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
129.02%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
455.37%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
20.23%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.00%
Compounded annual net profit growth over 5 years
Sequent Scientific Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SEQUENT — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sequent Scientific Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sequent Scientific Ltd (SEQUENT) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Sequent Scientific Ltd
About SEQUENT (Sequent Scientific Ltd)
Sequent Scientific Ltd is a dynamic pharmaceutical company dedicated to animal health, operating across Europe, Asia, and beyond. Sequent specializes in the development, manufactur...ing, and distribution of a diverse range of finished dosage formulations designed to improve the well-being of various animal populations. From farm animals vital to global food security to cherished family pets, Sequent provides innovative healthcare solutions in key therapeutic areas, including targeted nutrition, effective pain relief, comprehensive parasite control, advanced antibiotic treatments, and specialized gut health products. With a commitment to scientific excellence and animal welfare, Sequent strives to meet the evolving needs of the veterinary community and animal owners worldwide. Beyond its core product offerings, Sequent Scientific extends its expertise through comprehensive analytical services, ensuring the safety, efficacy, and quality of its formulations. The company's dedication to innovation is further demonstrated by its bespoke VET formulation services, tailored to meet specific client needs and address unique challenges in animal healthcare. These services encompass research and development, formulation optimization, and regulatory support, enabling Sequent to partner with veterinary professionals and other stakeholders to deliver cutting-edge solutions. By combining scientific rigor with a deep understanding of animal physiology, Sequent develops precisely tailored formulations to optimize animal health and performance. Sequent Scientific distinguishes itself through a customer-centric approach, building strong relationships with veterinarians, livestock producers, and pet owners alike. The company's commitment to quality, reliability, and innovation has established it as a trusted partner in the animal health industry. With a focus on sustainability and ethical practices, Sequent is dedicated to promoting responsible animal healthcare solutions that benefit both animals and the environment. Formerly known as PI Drugs & Pharmaceuticals Ltd., Sequent Scientific's evolution reflects its unwavering dedication to advancing animal health through continuous improvement and scientific discovery.
Company Details
Key Leadership
SEQUENT Share Price: Frequently Asked Questions
What is the current share price of Sequent Scientific Ltd?
Sequent Scientific Ltd (SEQUENT) trades at ₹188.78 on NSE and BSE. Market cap ₹12.24K (Cr). Educational data only.
What is the P/E ratio of Sequent Scientific Ltd?
Sequent Scientific Ltd has a P/E of 61.29x vs industry average 34.89x.
What is the Bull Run score for Sequent Scientific Ltd?
Sequent Scientific Ltd has a Bull Run score of 63.9/100 based on 25+ financial parameters.
Does Sequent Scientific Ltd pay dividends?
Sequent Scientific Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Sequent Scientific Ltd?
Sequent Scientific Ltd has ROE of 11.05%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sequent Scientific Ltd?
Sequent Scientific Ltd has debt-to-equity of 0.17.
Is Sequent Scientific Ltd a good investment?
Bull Run gives Sequent Scientific Ltd a score of 63.9/100. This is not investment advice — consult a SEBI-registered advisor.